Mumbai, Sept. 3 -- Risperidone will be available in single -dose vials, 25 mg per vial, 37.5 mg per vial, and 50 mg per vial and is bioequivalent to the reference listed drug (RLD), Risperdal Consta long-acting injection, and is indicated for the treatment of schizophrenia and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder.

This is Lupin's first product using proprietary Nanomi B.V.'s (Nanomi) technology and has a 180-day CGT exclusivity. Nanomi, a subsidiary of the company, focuses on the development of innovative long-acting injectable (LAI) medicines to improve health outcomes for patients.

As per IQVIA MAT July 2025, Risperidone extended-release injectable suspensi...